CA - Zomedica GAAP EPS of -$0.005 revenue of $4.2M
- Zomedica press release ( NYSE: ZOM ): Q2 GAAP EPS of -$0.005.
- Revenue of $4.2M (+26438.0% Y/Y).
- The increase was primarily due to the inclusion of our PulseVet platform which had revenues of $4.2 million consisting of instruments, trodes, and warranty services sold worldwide.
- We anticipate that costs of revenue will increase in 2022 in accordance with the increased revenue as described above.
- Zomedica had cash and cash equivalents of $186.8 million as of June 30, 2021, compared to $276.2 million as of June 30, 2021.
- Shares +0.19% AH.
For further details see:
Zomedica GAAP EPS of -$0.005, revenue of $4.2M